EVLO News and Press, Evelo Biosciences Inc. From 07/23/21

ChrisChrisW/iStock via Getty Images Goldman Sachs has lowered the rating on Seres Therapeutics (MCRB) to sell from neutral, citing the failure of the company to meet the primary endpoint for ulcerative colitis candidate SER-287 in a mid-stage trial. After losing more than half of market ...

Gainers: ImmunoPrecise Antibodies (IPA) +157%.India Globalization Capital (IGC) +74%.NRx Pharmaceuticals (NRXP) +56%.Universe Pharmaceuticals (UPC) +30%.Summit Wireless Technologies (WISA) +28%.Support.com (SPRT) +25%.Agrify Corporation (AGFY) +20%.PainReform (PRFX) +19%.Resources Connec...

Gainers: ImmunoPrecise Antibodies (IPA) +88%, PainReform (PRFX) +48%, NRx Pharmaceuticals (NRXP) +30%, NeuroMetrix (NURO) +27%, Universe Pharmaceuticals (UPC) +18%.Losers: Seres Therapeutics (MCRB) -57%, Jupiter Wellness (JUPW)&...

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 202...

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that on June 14, 2021, Mark Plinio commenced his services as Evelo’s Chief Commercial ...

Inflation is here; and that means these groups ought to be on your radar. The best stocks within every sector now. Over 20 new stocks join our 'best stocks' list this week. For further details see: The Stocks To Focus On Today

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that given accelerating growth to later-stage development and the anticipated hiring and expa...

Market leadership by sector and market cap. Sectors remain tilted toward mid-cycle ideas. However, stock-specific ideas are available in every basket. For further details see: The Top Stocks You Can Buy Now

Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture PR Newswire CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's in...

Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening PR Newswire CAMBRIDGE, Mass. , May 19, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet'...